Relevant bibliographies by topics / Eribulin Mesylate

Academic literature on the topic 'Eribulin Mesylate'

Author: Grafiati
Published: 6 September 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Eribulin Mesylate.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Eribulin Mesylate"

1

Huyck, Timothy K., William Gradishar, Fil Manuguid, and Peter Kirkpatrick. "Eribulin mesylate." Nature Reviews Drug Discovery 10, no. 3 (March 2011): 173–74. http://dx.doi.org/10.1038/nrd3389.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Jain, Sarika, and Linda T. Vahdat. "Eribulin Mesylate." Clinical Cancer Research 17, no. 21 (August 22, 2011): 6615–22. http://dx.doi.org/10.1158/1078-0432.ccr-11-1807.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Edwards, Michael S., Dominic A. Solimando, and J. Aubrey Waddell. "Eribulin Mesylate and Denosumab." Hospital Pharmacy 46, no. 4 (April 2011): 247–53. http://dx.doi.org/10.1310/hpj4604-247.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Verdaguer, Helena, Idoia Morilla, and Ander Urruticoechea. "Eribulin Mesylate in Breast Cancer." Women's Health 9, no. 6 (November 2013): 517–26. http://dx.doi.org/10.2217/whe.13.61.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Nieder, Carsten, Gro Aandahl, and Astrid Dalhaug. "A Case of Brain Metastases from Breast Cancer Treated with Whole-Brain Radiotherapy and Eribulin Mesylate." Case Reports in Oncological Medicine 2012 (2012): 1–3. http://dx.doi.org/10.1155/2012/537183.

Full text
Abstract:
Patients with triple receptor-negative breast cancer often develop aggressive metastatic disease, which also might involve the brain. In many cases, systemic and local treatment is needed. It is important to consider the toxicity of chemo- and radiotherapy, especially when newly approved drugs become available. Randomised studies leading to drug approval often exclude patients with newly diagnosed brain metastases. Here we report our initial experience with eribulin mesylate and whole-brain radiotherapy (WBRT) in a heavily pretreated patient with multiple brain, lung, and bone metastases from triple receptor-negative breast cancer. Eribulin mesylate was given after 4 previous lines for metastatic disease. Two weeks after the initial dose, that is, during the first cycle, the patient was diagnosed with 5 brain metastases with a maximum size of approximately 4.5 cm. She continued chemotherapy and received concomitant WBRT with 10 fractions of 3 Gy. After 3 cycles of eribulin mesylate, treatment was discontinued because of newly diagnosed liver metastases and progression in the lungs. No unexpected acute toxicity was observed. The only relevant adverse reactions were haematological events after the third cycle (haemoglobin 9.5 g/dL, leukocytes3.1×109/L). The patient died from respiratory failure 18.5 months from diagnosis of metastatic disease, and 2.7 months from diagnosis of brain metastases. To the best of our knowledge, this is the first report on combined WBRT and eribulin mesylate.
APA, Harvard, Vancouver, ISO, and other styles
6

Barnato, Sara E., Jacqueline Sara Jeruss, Kevin P. Bethke, Nora M. Hansen, Seema Ahsan Khan, Jamie H. Von Roenn, Steven T. Rosen, et al. "Phase II neoadjuvant trial with carboplatin and eribulin mesylate in patients with triple-negative breast cancer." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): TPS1134. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.tps1134.

Full text
Abstract:
TPS1134 Background: Several neoadjuvant trials have been conducted in triple negative breast cancer (TNBC) with platinum agents with pathologic complete response (pCR) ranging from 16%-32%. Eribulin mesylate, a nontaxane microtubule dynamics inhibitor, has clinical activity as monotherapy in breast cancer and other solid tumors. A recent phase I trial found the combination of eribulin mesylate with carboplatin was well tolerated and showed activity in advanced solid tumors. The recommended dose for future trials was eribulin mesylate 1.1 mg/m2 and carboplatin AUC6. We proposed a neoadjuvant phase II trial with the combination of carboplatin and eribulin in patients with TNBC. Methods: This is a non-randomized, open-label, multi-center, phase II clinical trial of eribulin and carboplatin enrolling histologically-confirmed TNBC patients. Our primary endpoint is to determine the pCR in TNBC patients treated with the combination of carboplatin and eribulin. Secondary endpoints include determination of the clinical response rate, toxicity evaluation and measurement of stem cell and TLE3 as a biomarker of response to eribulin therapy. To obtain an alpha of 0.10 and a power of 0.90, a sample size of 30 patients is required to detect a pCR rate >=30%. 10 of the planned 30 patients have been enrolled to date. Treatment will be given every 3 weeks for a total of 4 cycles of therapy. There will be an initial safety run-in to evaluate the appropriate dose of eribulin in this population. The first 10 patients will receive eribulin at 1.4 mg/m2 (intravenously over 2-5 minutes) followed by carboplatin AUC=6 (intravenously over 30 minutes). After the 10th patient has been enrolled, the study will be temporarily suspended pending review; toxicity will be assessed for these first 10 patients (cycle 1 only) to assess whether this dose of eribulin will be used for the remaining patients or if a reduction to a dose of 1.1 mg/m2 will be required. Definitive surgery will be performed 3-8 weeks after completion of therapy, which will conclude the duration of the study. Clinical Trial Registry Number NCT01372579.
APA, Harvard, Vancouver, ISO, and other styles
7

Pullela, Srinivas Venkata, Vinod Acharya, Nagarjuna Reddy, Jayvant Harlikar, Amar Kulkarni, Rakesh Chavan, Ajay Yadav, Shuvendu Manna, and Angshuman Ghosh. "Structural corroboration of two important building blocks of the anticancer drug eribulin mesylate through two-dimensional NMR and single-crystal X-ray diffraction studies." Acta Crystallographica Section C Structural Chemistry 72, no. 1 (January 1, 2016): 14–20. http://dx.doi.org/10.1107/s2053229615022305.

Full text
Abstract:
Eribulin mesylate, one of the most synthetically challenging drugs to date, possesses 19 stereocentres in its structure and ascertaining the absolute stereochemistry at every stage of the 64-stage synthesis is crucial. In our quest to synthesize eribulin, we identified two critical building blocks of this molecule, namely 3,4:6,7-di-O-cyclohexylidene-D-glycero-α-L-talo-heptopyranose methanol monosolvate, C19H30O7·CH3OH, and (2R,3R,4R,5S)-5-allyl-2-[(S)-2,3-dihydroxypropyl]-4-[(phenylsulfonyl)methyl]tetrahydrofuran-3-ol, C17H24O6S, for which two-dimensional NMR (2D-NMR) data were not sufficient to prove the absolute configuration. To ensure structural integrity, single-crystal X-ray diffraction data were obtained to confirm the structures. This information provides useful insights into the structural framework of the large eribulin mesylate molecule.
APA, Harvard, Vancouver, ISO, and other styles
8

Nasim, Muhammad Yaser, Ruth Plummer, T. R. Jeffry Evans, Rosemary Morrison, David Alan Anthoney, Sophie Haney, Ayman Madi, et al. "A phase Ib dose-escalation study of eribulin mesylate in combination with capecitabine in patients with advanced/metastatic cancer." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 2552. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.2552.

Full text
Abstract:
2552 Background: Eribulin mesylate is a microtubule dynamics inhibitor approved by FDA for patients (pts) with metastatic breast cancer after treatment with at least two prior chemotherapeutic regimens. This Phase Ib, open-label dose-escalation study determined the maximum tolerated dose (MTD) of eribulin in combination with capecitabine. Methods: Pts with advanced solid malignancies refractory to standard therapies, adequate organ function and ECOG performance status ≤2 received eribulin mesylate (2–5-min IV) by Schedule 1 (1.2, 1.6 or 2.0 mg/m2 on Day 1) or Schedule 2 (0.7, 1.1 or 1.4 mg/m2 on Days 1 and 8), in combination with twice-daily oral capecitabine 1000 mg/m2 Days 1-14 every 21 days. The MTD was defined as the highest dose in each schedule where ≤1/6 pts experienced dose-limiting toxicity (DLT). Safety and pharmacokinetics (PK) were assessed. Results: Of the 34 pts recruited, 19 (53% male; median age 62 years; 42% ECOG 0, 58% ECOG 1) and 15 (33% male; median age 61 years; 33% ECOG 0, 60% ECOG 1, 7% ECOG 2) were enrolled in Schedules 1 and 2, respectively. Most common tumor types were large intestine (20.6%), lung/bronchus (17.7%) and breast (14.7%). DLTs are shown in the table; there were no unexpected toxicities with the combination. The MTD for eribulin mesylate was 1.6 and 1.4 mg/m2 for Schedules 1 and 2, respectively, in combination with capecitabine 1000 mg/m2 twice-daily. Eribulin PK were dose proportional and independent of schedule or capecitabine co-administration. Combination with eribulin had no effect on the disposition of capecitabine and its metabolites. Although sample size was small, preliminary signs of efficacy were observed. Conclusions: The combination of eribulin and capecitabine was well tolerated with no unexpected safety findings. Schedule 2 MTD (1.4 mg/m2 Days 1 and 8) delivered a higher dose intensity of eribulin than Schedule 1 and was selected for evaluation in an ongoing Phase II breast cancer study. [Table: see text]
APA, Harvard, Vancouver, ISO, and other styles
9

Iwamoto, Mitsuhiko, Nayuko Sato, Risa Terasawa, Hiroya Fujioka, Yuko Takahashi, Kosei Kimura, Satoru Tanaka, and Kazuhisa Uchiyama. "Phase II study of eribulin mesylate as first- or second-line therapy for metastatic HER2-negative breast cancer." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): TPS1140. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.tps1140.

Full text
Abstract:
TPS1140 Background: Eribulin mesylate is a nontaxane microtubule dynamics inhibitor that is approved in patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens (including an anthracycline and a taxane) for metastatic breast cancer. In a previous phase III study, eribulin mesylate demonstrated to significant improvement in overall survival in patients with heavily pretreated, locally recurrent or metastatic breast cancer when compared to treatment of physician’s choice. The majority of patients were HER2-negative and all had previously failed 2 or more regimens. Overall, the tolerability and positive phase III findings in this patient population suggest eribulin mesylate may provide a treatment advantage when given earlier in the course of therapy for HER2-negative, metastatic breast cancer. Methods: This study is phase II, multicenter, open-label, single-arm in patients with HER2-negative metastatic breast cancer who have been treated with chemotherapeutic regimens including an antheracycline and a taxane. Eribulin mesylate (1.4mg/m2) will be given on days 1 and 8 of each 21-day cycle. The primary endpoint is objective response rate, and secondary endpoints include duration of response, progression-free survival, overall survival, the safety of the treatment, and quality of life. Eligibility Criteria: Patients must have confirmed HER2-negative metastatic breast cancer with at least 4 weeks since prior neoadjuvant or adjuvant chemotherapy, and have not received over 2 chemotherapeutic regimens for metastatic disease. Additional eligibility criteria include adequate performance status (ECOG PS:0-2) and end organ/marrow function, and ejection fraction > 50%. Accrual: This study began in December 2012. The expected end of accrual of 35 patients will be the last quarter 2015.
APA, Harvard, Vancouver, ISO, and other styles
10

Raftopoulos, Harry, Joseph Aisner, Kirushna Kumar, Sanjay Goel, Christian Dittrich, Minish Jain, Prashanth Gopalakrishna, Paloma Salazar, Beverley Jones, and Daniel Peter Petrylak. "Phase Ib extension study of eribulin mesylate in combination with carboplatin in patients with chemotherapy-naive advanced non-small cell lung cancer (NSCLC)." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): e19145-e19145. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e19145.

Full text
Abstract:
e19145 Background: Eribulin mesylate as monotherapy has shown antitumor activity in patients with advanced NSCLC that progressed during or after platinum-based doublet chemotherapy (Spira AI et al. Clin Lung Cancer 2012; 13:31-38.). Following evidence of additive activity with eribulin and carboplatin in lung cancer cell lines, a phase Ib, dose-escalation study determined the maximum tolerated dose and optimum administration sequence of the combination as eribulin mesylate 1.1 mg/m2 (0.97 mg/m2 eribulin as free base) followed by carboplatin AUC 6. We report results from an extension arm that investigated the efficacy and safety of this combination in chemo-naïve patients with advanced NSCLC. Methods: Chemo-naïve patients with histologically or cytologically confirmed advanced NSCLC (stage IIIB or IV) with measurable disease were enrolled. Eribulin mesylate was administered intravenously (i.v.) on days 1 and 8 every 21 days, along with carboplatin i.v. on day 1. Efficacy assessments included best overall objective response rate (ORR; RECIST), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and duration of response (DOR). Adverse events (AEs) were also recorded. Results: 12 patients were accrued (11 male, 1 female) with a median age of 66.5 (range 42-74) years. For the 11 patients evaluable for efficacy, overall ORR was 27.3% (all partial responses) and DCR was 63.6%. Median (range) OS was 12.1 (1.6-12.1) months (5 patients still alive); PFS was 4.2 (0.03+-5.8+) months (upper value censored as 1 patient still responding at final visit); and DOR was 2.9 (2.8-3.1+) months. The most common AEs ≥grade 3 were thrombocytopenia (n=6), neutropenia (n=5), febrile neutropenia (n=4), anemia (n=3), and dyspnea, hypokalemia, leukopenia, and pneumonia (n=2 each). Conclusions: The combination of eribulin and carboplatin yielded no unexpected safety findings. Given the evolving treatment practices for NSCLC, further studies involving larger numbers of patients are warranted, with consideration given to specific histologic subgroups. Clinical trial information: NCT00268905.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Eribulin Mesylate"

1

Bauer, Armin. "Story of Eribulin Mesylate: Development of the Longest Drug Synthesis." In Topics in Heterocyclic Chemistry, 209–70. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/7081_2016_201.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

"Eribulin Mesylate." In ASHP® Injectable Drug Information™, 616. ASHP, 2021. http://dx.doi.org/10.37573/9781585286850.149.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Chase, Charles, Hyeong-­wook Choi, Atsushi Endo, Francis Fang, and John Orr. "Development and Commercialization of a Fully Synthetic Marine Natural Product Analogue, Halaven® (Eribulin Mesylate)." In Marine Biomedicine, 497–530. CRC Press, 2015. http://dx.doi.org/10.1201/b19081-21.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Eribulin Mesylate"

1

Reyderman, Larisa, Timothy J. Carrothers, Borje Darpo, and Allan Kristensen. "Abstract B193: Analysis of the concentration-QTc relationship for eribulin mesylate." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 12-16, 2011; San Francisco, CA. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1535-7163.targ-11-b193.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Albu, Diana I., Namita Kumar, Galina Kusnetzov, Shanqin Xu, Bruce Littlefield, and Mary Woodall-Jappe. "Abstract B90: Eribulin mesylate alters immune homeostasis in mice bearing syngeneic tumors." In Abstracts: AACR Special Conference on Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances; December 2-5, 2012; Miami, FL. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.tumimm2012-b90.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Tanriverdi, Gamze. "Evaluation of eribulin mesylate efficacy on proliferation and apoptosis of C6 Glioblastoma cells." In 15th International Congress of Histochemistry and Cytochemistry. Istanbul: LookUs Scientific, 2017. http://dx.doi.org/10.5505/2017ichc.pp-126.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wozniak, Krystyna, Ying Wu, Kenichi Nomoto, Bruce A. Littlefield, Christopher DesJardins, Edgar Schuck, Phil Saxton, Nancy Wong, and Barbara S. Slusher. "Abstract 4653: Pharmacokinetics and biodistribution of eribulin mesylate, paclitaxel, and ixabepilone in mouse." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-4653.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wozniak, Krystyna, Ying Wu, Bruce A. Littlefield, Kenichi Nomoto, Christopher DesJardins, Yanke Yu, George Lai, Larisa Reyderman, and Barbara S. Slusher. "Abstract 4503: Pharmacokinetics and pharmacodynamic analysis of eribulin mesylate and paclitaxel in mouse." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-4503.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Asano, Makoto, Kenji Hyodo, Yanke Yu, Edgar Schuck, Junji Matsui, Hiroshi Ishihara, Hiroshi Kikuchi, and Kenichi Nomoto. "Abstract 4543: Characterization of the liposomal formulation of eribulin mesylate (E7389) in mice." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-4543.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Albu, Diana I., Bruce A. Littlefield, and Mary Woodall-Jappe. "Abstract 1227: Macrophage depletion enhances the anticancer efficacy of eribulin mesylate in mice bearing syngeneic tumors." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-1227.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Utsumi, T., T. Hayashi, N. Kobayashi, M. Hikichi, K. Ushimado, Y. Ri, S. Nakano, K. Fujii, and T. Ando. "Abstract P5-15-10: Eribulin mesylate (eribulin) showed inhibitory effects on epithelial-mesenchymal transition (EMT) in tumors of metastatic breast cancer patients. -First preliminary report of a prospective study-." In Abstracts: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, Texas. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.sabcs16-p5-15-10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Meattini, Icro, Vieri Scotti, Carla De Luca Cardillo, Beatrice Detti, Vanessa Di Cataldo, and Lorenzo Livi. "Abstract P1-15-21: Safety of eribulin mesylate and concomitant palliative radiotherapy for metastatic breast cancer: A single-center experience." In Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-p1-15-21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Schwartzberg, Lee, Kristi McIntyre, Joyce O'Shaughnessy, Stefan Glück, Erhan Berrak, James Song, David Cox, and Linda Vahdat. "Abstract P5-17-02: Quality of life in patients receiving first-line eribulin mesylate for HER2- locally recurrent or MBC." In Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-p5-17-02.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Eribulin Mesylate' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography